Search research articles
Contact Us
Filters
Showing results (871-880 of 1,023) with videos related to
Page
of 103
Sort By:
European Journal of Heart Failure
|
February 14, 2015
Clinical characteristics and outcomes of patients with angina and heart failure in the CHARM (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity) Programme
Athar A Badar, Ana C Perez-Moreno, Nathaniel M Hawkins, et al.
European Heart Journal. Cardiovascular Pharmacotherapy
|
December 28, 2020
Heterogeneity of diabetes as a risk factor for major adverse cardiovascular events in anticoagulated patients with atrial fibrillation: an analysis of the ARISTOTLE trial
Raffaele De Caterina, Giuseppe Patti, Johan Westerbergh, et al.
American Heart Journal
|
June 7, 2016
A clustered randomized trial to IMProve treatment with AntiCoagulanTs in patients with Atrial Fibrillation (IMPACT-AF): design and rationale
Meena P Rao, Andrea O Ciobanu, Renato D Lopes, et al.
Journal of the American Heart Association
|
October 26, 2017
Impact of Regional Systems of Care on Disparities in Care Among Female and Black Patients Presenting With ST-Segment-Elevation Myocardial Infarction
Tomoya T Hinohara, Hussein R Al-Khalidi, Christopher B Fordyce, et al.
Circulation
|
February 16, 2006
Clinical correlates and consequences of anemia in a broad spectrum of patients with heart failure: results of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Program
Eileen O'Meara, Tim Clayton, Margaret B McEntegart, et al.
European Heart Journal
|
August 17, 1999
Contemporary management of patients with left ventricular systolic dysfunction. Results from the Study of Patients Intolerant of Converting Enzyme Inhibitors (SPICE) Registry
B A Bart, G Ertl, P Held, et al.
Circulation
|
January 19, 2021
Apixaban or Vitamin K Antagonists and Aspirin or Placebo According to Kidney Function in Patients With Atrial Fibrillation After Acute Coronary Syndrome or Percutaneous Coronary Intervention: Insights From the AUGUSTUS Trial
Ziad Hijazi, John H Alexander, Zhuokai Li, et al.
Circulation. Heart Failure
|
May 1, 2023
Prognostic Importance of NT-proBNP (N-Terminal Pro-B-Type Natriuretic Peptide) Following High-Risk Myocardial Infarction in the PARADISE-MI Trial
Karola S Jering, Brian L Claggett, Marc A Pfeffer, et al.
American Heart Journal
|
September 24, 2017
Regional differences in presentation and antithrombotic treatment of patients with atrial fibrillation: Baseline characteristics from a clustered randomized trial to IMProve treatment with AntiCoagulanTs in patients with atrial fibrillation (IMPACT-AF)
Dragos Vinereanu, Hussein R Al-Khalidi, Meena P Rao, et al.
American Heart Journal
|
January 2, 2023
Prehospital treatment with zalunfiban (RUC-4) in patients with ST- elevation myocardial infarction undergoing primary percutaneous coronary intervention: Rationale and design of the CELEBRATE trial
Sem A O F Rikken, Abi Selvarajah, Renicus S Hermanides, et al.
Page
of 103
Search research articles
Search
Showing results (871-880 of 1,023) with videos related to
Sort By:
Page
of 103
European Journal of Heart Failure
|
February 14, 2015
Clinical characteristics and outcomes of patients with angina and heart failure in the CHARM (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity) Programme
Athar A Badar, Ana C Perez-Moreno, Nathaniel M Hawkins, et al.
European Heart Journal. Cardiovascular Pharmacotherapy
|
December 28, 2020
Heterogeneity of diabetes as a risk factor for major adverse cardiovascular events in anticoagulated patients with atrial fibrillation: an analysis of the ARISTOTLE trial
Raffaele De Caterina, Giuseppe Patti, Johan Westerbergh, et al.
American Heart Journal
|
June 7, 2016
A clustered randomized trial to IMProve treatment with AntiCoagulanTs in patients with Atrial Fibrillation (IMPACT-AF): design and rationale
Meena P Rao, Andrea O Ciobanu, Renato D Lopes, et al.
Journal of the American Heart Association
|
October 26, 2017
Impact of Regional Systems of Care on Disparities in Care Among Female and Black Patients Presenting With ST-Segment-Elevation Myocardial Infarction
Tomoya T Hinohara, Hussein R Al-Khalidi, Christopher B Fordyce, et al.
Circulation
|
February 16, 2006
Clinical correlates and consequences of anemia in a broad spectrum of patients with heart failure: results of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Program
Eileen O'Meara, Tim Clayton, Margaret B McEntegart, et al.
European Heart Journal
|
August 17, 1999
Contemporary management of patients with left ventricular systolic dysfunction. Results from the Study of Patients Intolerant of Converting Enzyme Inhibitors (SPICE) Registry
B A Bart, G Ertl, P Held, et al.
Circulation
|
January 19, 2021
Apixaban or Vitamin K Antagonists and Aspirin or Placebo According to Kidney Function in Patients With Atrial Fibrillation After Acute Coronary Syndrome or Percutaneous Coronary Intervention: Insights From the AUGUSTUS Trial
Ziad Hijazi, John H Alexander, Zhuokai Li, et al.
Circulation. Heart Failure
|
May 1, 2023
Prognostic Importance of NT-proBNP (N-Terminal Pro-B-Type Natriuretic Peptide) Following High-Risk Myocardial Infarction in the PARADISE-MI Trial
Karola S Jering, Brian L Claggett, Marc A Pfeffer, et al.
American Heart Journal
|
September 24, 2017
Regional differences in presentation and antithrombotic treatment of patients with atrial fibrillation: Baseline characteristics from a clustered randomized trial to IMProve treatment with AntiCoagulanTs in patients with atrial fibrillation (IMPACT-AF)
Dragos Vinereanu, Hussein R Al-Khalidi, Meena P Rao, et al.
American Heart Journal
|
January 2, 2023
Prehospital treatment with zalunfiban (RUC-4) in patients with ST- elevation myocardial infarction undergoing primary percutaneous coronary intervention: Rationale and design of the CELEBRATE trial
Sem A O F Rikken, Abi Selvarajah, Renicus S Hermanides, et al.
Page
of 103